SOLA Biosciences has shared new preclinical proof-of-concept data for SOL-257, an experimental gene therapy aimed at addressing a key biological driver of ALS. The therapy is designed to reduce the harmful effects of misfolded TDP-43, a protein linked to nerve cell damage in many people with the disease. By targeting an underlying cause rather than symptoms alone, this approach could represent a meaningful shift in how ALS is treated. The findings support continued development of SOL-257 and highlight the promise of gene therapies to deliver more durable, disease-modifying solutions for ALS patients. Read more (via Business Wire)